Ascendis Pharma to Present Hypoparathyroidism, Achondroplasia Program Updates
Ascendis Pharma A/S announced that recent advancements in its hypoparathyroidism and achondroplasia programs will be featured at the upcoming ASBMR 2026 annual meeting.
Ascendis Pharma A/S announced that recent advancements in its hypoparathyroidism and achondroplasia programs will be featured at the upcoming ASBMR 2026 annual meeting.